Skip to main content

View full-text article in PMC

. 2020 Mar 12;46(4):557–562. doi: 10.1590/S1677-5538.IBJU.2019.0154

Table 1. Clinical characteristics of the patients in both groups.

	Group I (n=159)	Group II (n=93)	p
Age (years)	61.82 (±7.39)	62.28 (±6.16)	0.612
Body mass index (BMI) (kg/m²)	26.10 (22.80-27.70)	26.10 (22.80-28.30)	0.966
Total prostate volume (mm³)	51.62 (34.00-71.73)	50.00 (40.00-60.00)	0.627
Serum PSA level (ng/dL)	6.99 (5.01-10.10)	8.01 (5.05-9.12)	0.615
Number of biopsy cores (n)	16.0 (15.0-19.0)	12.0 (11.0-12.0)	<0.001
Malignancy detection rate (n, %)	70/159 (44.0%)	24/93 (25.8%)	0.004

PSA = Prostate specific antigen